Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Melody A. Cobleigh"'
Autor:
James N. Ingle, George Thomas Budd, William C. Wood, Silvana Martino, Melody A. Cobleigh, Larry Norton, Mark L. Graham, Ruta D. Rao, Robert Gray
Publikováno v:
Medical Oncology. 28:39-47
Fenretinide and tamoxifen have additive antitumor effects preclinically. We performed a randomized, placebo-controlled, double-blind adjuvant trial in breast cancer patients treated for 5 years with tamoxifen, with or without fenretinide. Between Oct
Autor:
William Novotny, Virginia K. Langmuir, Amy Vassel, James D. Reimann, Latrice Haney, Melody A. Cobleigh, Kathy D. Miller, George W. Sledge
Publikováno v:
Seminars in oncology. 30(5 Suppl 16)
Vascular endothelial growth factor promotes angiogenesis, an important mediator of growth and metastasis in human breast cancer. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor, is under investigation as an anti-angiogenic ag
Autor:
R G Mehta, J B Ashenhurst, Alfred W. Rademaker, J L Wade rd, Melody A. Cobleigh, K Dowlatshahi, R C Moon, A B Benson rd, T A Deutsch, F Minn
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 11(3)
PURPOSE Considerable attention has been focused on the chemopreventive properties of fenretinide against carcinogen-induced rodent mammary cancer. Less is known about its direct antitumor effects. The combination of tamoxifen and fenretinide is more
Autor:
Kathy D. Miller, B. J. Klencke, Meghna Samant, Nancy E. Davidson, Maura N. Dickler, Tamara Shenkier, Suman Bhattacharya, E. A. Perez, Julie Gralow, Melody A. Cobleigh
Publikováno v:
Journal of Clinical Oncology. 26:1036-1036
1036 Background: E2100 was an open-label, multi-center, randomized, Phase III trial comparing P to P+B as initial chemotherapy for MBC. The original analysis based on investigator-assessed progress...
Autor:
David M. Loesch, Nicholas J. Robert, Melody A. Cobleigh, D. J. Slamom, Kathy S. Albain, Brian Leyland-Jones, Des Ilegbodu, Lina Asmar, Robert N. Raju, R. J. Belt
Publikováno v:
Journal of Clinical Oncology. 22:573-573
573 Purpose: This randomized multicenter phase III trial evaluated the efficacy and safety of trastuzumab with paclitaxel 175 mg/m2 and carboplatin AUC=6 (TPC) versus trastuzumab with paclitaxel 175 mg/m2 (TP) in women with HER-2 overexpressing metas